QSPainRelief-STRAT
Unknown statusNot applicableNCT06244706
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Investigating the clinical outcomes of drug combinations (opioid + medication acting on the central nervous system) in patients suffering from persistent pain (pain lasting for at least three months) through patient-reported outcomes.
Study details
- Official title
- QSPainRelief-STRAT: A Questionnaire-based Evaluation of Perceived Clinical Outcome in Patients With Persistent Pain Receiving an Opioid and Non-opioid Treatment Combination, Stratified According to Age and Sex
- Conditions
- Chronic Pain
- Analgesia
- Adverse Drug Event
- Drug Interaction
- Interventions
- Combination product: Opioid drug + CNS-acting add-on drug
- Sponsor
- Université Catholique de Louvain
- Collaborators
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Start date
- 2024-02-01
- Primary completion
- 2025-12-31
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Total sites listed
- 0
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Aged over 18 years. 2. Current treatment with an opioid for the treatment of pain, along with possible other drugs (see Table 1 for the list of eligible opioid medications - patients will be invited to indicate their treatment by selecting its name using a dropdown list). 3. Decision by the treating physician to introduce an additional non-opioid CNS-acting treatment such as an antiepileptic, an anti-depressant or benzodiazepine (see Table 2 for the list of eligible medications - patients will be invited to indicate their treatment by selecting its name using a dropdown list). 4. Capacity to understand and provide informed consent. Exclusion Criteria: 1. Insufficient French language skills. 2. Epilepsy treated by an anti-epileptic. 3. Alzheimer's disease. 4. Parkinson's disease 5. History of cancer diagnosed less than 5 years ago, treated by chemotherapy or radiotherapy.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06244706